Updated Enlivex (ENLV) investor deck tied to F-3 and S-8 filings

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. filed a Form 6-K stating that on August 18, 2025 it posted an updated investor presentation on its website. The company furnished this presentation as Exhibit 99.1 to the report, making it available to the market through the SEC system.

The information on slides 10 through 24 of the presentation is explicitly incorporated by reference into Enlivex’s existing registration statements on Forms S-8 and F-3, including an F-3MEF. This means those specific slides now form part of the legal disclosure package that supports Enlivex’s registered securities offerings in the United States.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: August 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

On August 18, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), posted an updated investor presentation on its website. A copy of such presentation is furnished as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference. The information on slides 10 through 24, inclusive, of such investor presentation is incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-286956), filed with the Securities and Exchange Commission.

Exhibit No.
99.1	Investor Presentation

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:  Title:	Oren Hershkovitz Chief Executive Officer

Date: August 18, 2025

2

FAQ

What did Enlivex Therapeutics (ENLV) disclose in this Form 6-K?

Enlivex Therapeutics Ltd. reported that on August 18, 2025 it posted an updated investor presentation on its website and furnished that presentation as Exhibit 99.1 to the Form 6-K.

How is the new Enlivex (ENLV) investor presentation used in its SEC filings?

The company states that information on slides 10 through 24 of the investor presentation is incorporated by reference into its registration statements on Forms S-8, F-3 and F-3MEF that are on file with the SEC.

Which Enlivex (ENLV) registration statements reference this investor presentation?

Slides 10 through 24 are incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF with file numbers 333-256799, 333-232413, 333-232009, 333-252926 and 333-286956.

Where can investors find the updated Enlivex (ENLV) investor presentation?

Enlivex states that the updated investor presentation was posted on its website and also furnished to the SEC as Exhibit 99.1 to this Form 6-K, making it accessible through the SEC’s EDGAR system.

Does this Enlivex (ENLV) Form 6-K announce any new financing or major transaction?

This Form 6-K describes the posting and furnishing of an updated investor presentation and the incorporation of certain slides into existing registration statements; it does not describe any new financing terms or major transaction.

Who signed the Enlivex (ENLV) Form 6-K?

The Form 6-K was signed on behalf of Enlivex Therapeutics Ltd. by Chief Executive Officer Oren Hershkovitz.